| Identification | Back Directory | [Name]
Boron, [1-?(4-?amino-?6,?7-?dimethoxy-?2-?quinazolinyl)?-?4-?[3-?[5-?[(3,?5-?dimethyl-?2H-?pyrrol-?2-?ylidene-?κN)?methyl]?-?1H-?pyrrol-?2-?yl-?κN]?-?1-?oxopropyl]?piperazinato]?difluoro-?, (T-?4)?- | [CAS]
175799-93-6 | [Synonyms]
Boron, [1-?(4-?amino-?6,?7-?dimethoxy-?2-?quinazolinyl)?-?4-?[3-?[5-?[(3,?5-?dimethyl-?2H-?pyrrol-?2-?ylidene-?κN)?methyl]?-?1H-?pyrrol-?2-?yl-?κN]?-?1-?oxopropyl]?piperazinato]?difluoro-?, (T-?4)?- |
| Hazard Information | Back Directory | [Uses]
BODIPY FL prazosin is a fluorescent α1-adrenergic antagonist with Ki values of 14.5, 43.3 nM for α1a-AR and α1b-AR, respectively. BODIPY FL prazosin also is a fluorescent ligand with the excitation and emission wavelengths are 485 and 535 nm, respectively. BODIPY FL prazosin can be used for study the differences in the subcellular localization of α1-adrenoceptor subtypes[1][2][3]. | [IC 50]
α1A-adrenergic receptor: 14.5 nM (Ki); α1B-adrenergic receptor: 43.3 nM (Ki) | [References]
[1] Sugawara T, et al. Differences in the subcellular localization of alpha1-adrenoceptor subtypes can affect the subtype selectivity of drugs in a study with the fluorescent ligand BODIPY FL-prazosin. Life Sci. 2002 Mar 22;70(18):2113-24. DOI:10.1016/s0024-3205(01)01533-8
[2] Cerveny L, et al. Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents. Epilepsia. 2006 Mar;47(3):461-8. DOI:10.1111/j.1528-1167.2006.00453.x
[3] Fuchs R, et al. α1-adrenergic drugs exhibit affinity to a thapsigargin-sensitive binding site and interfere with the intracellular Ca2+ homeostasis in human erythroleukemia cells. Exp Cell Res. 2011 Dec 10;317(20):2969-80. DOI:10.1016/j.yexcr.2011.08.003 |
|
|